Table 4 Association between STC-1 expression and clinicopathological features
Characteristics | No. | peripheral blood | bone marrow | ||
|---|---|---|---|---|---|
STC-1 (+) (%) | P-value | STC-1 (+) (%) | P-value | ||
Gender | Ā | Ā | 0.674 | Ā | 0.429 |
āMale | 54 | 19(35.2%) | Ā | 10(18.5%) | Ā |
āFemale | 31 | 13(41.9%) | Ā | 8 (25.8%) | Ā |
Age | Ā | Ā | 0.242 | Ā | 0.446 |
ā<60 | 35 | 11 (31.4%) | Ā | 6(17.1%) | Ā |
āā„60 | 50 | 22 (44.0%) | Ā | 12(24.0%) | Ā |
Tumor site | Ā | Ā | 0.632 | Ā | 0.547 |
āUpper thoracic | 17 | 5 (29.4%) | Ā | 4 (23.5%) | Ā |
āMiddle thoracic | 33 | 12 (36.4%) | Ā | 5 (15.2%) | Ā |
āLower thoracic | 35 | 15 (42.9%) | Ā | 9 (25.7%) | Ā |
Differentiation | Ā | Ā | 0.615 | Ā | 0.575 |
āWell | 18 | 5 (27.8%) | Ā | 3 (16.7%) | Ā |
āModerate | 38 | 15(39.5%) | Ā | 7 (18.4%) | Ā |
āPoor | 29 | 12(41.4%) | Ā | 8 (27.6%) | Ā |
T status | Ā | Ā | 0.583 | Ā | 0.329 |
āT1ā~ā2 | 51 | 18 (35.3%) | Ā | 9(17.6%) | Ā |
āT3ā~ā4 | 34 | 14 (41.2%) | Ā | 9(26.5%) | Ā |
Lymph metastasis | Ā | Ā | 0.000* | Ā | 0.013* |
āN0 | 41 | 7(17.1%) | Ā | 4(9.76%) | Ā |
āN1/N2/N3 | 44 | 25(56.8%) | Ā | 14(31.8%) | Ā |
Clinical stage | Ā | Ā | 0.020* | Ā | 0.029* |
āI/II | 43 | 11(25.6%) | 23 | 5(11.6%) | 20 |
āIII/IV | 42 | 21(50.0%) | 33 | 13(31.0%) | 9 |